Summary: Evaluated telmisartan versus ramipril versus the combination of both in patients with coronary disease, peripheral arterial disease, stroke and diabetes. The primary composite endpoint of death from cardiovascular causes, MI, stroke or hospitalization for heart failure was no different between the two drugs (telmisartan non-inferior). The combination of the two had no benefit and increased the risk of renal impairment.
N Engl J Med. 2008 Apr 10;358(15):1547-59.
Eponym: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial